http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김가영 ( Ka Young Kim ),차선아 ( Seon Ah Cha ),김영운 ( Young Woon Kim ),유효경 ( Hyo Kyeong Yu ),임예지 ( Ye Jee Lim ),류시영 ( Si Young You ),김성경 ( Sung Kyoung Kim ),김치홍 ( Chi Hong Kim ),김훈교 ( Hoon Kyo Kim ) 대한결핵 및 호흡기학회 2012 Tuberculosis and Respiratory Diseases Vol.72 No.2
Cough syncope is characterized by the loss of consciousness occurring after vigorous coughings. There are approximately 90 reported cases of cough syncope within the medical literature. Most cases involving middle aged, overweight and chronic bronchitic male smokers. Although many studies have been published in the medical literature, the mechanism and pathophysiology for cough syncope has not been well established. Cough syncope is treated by correcting the underlying cause when identified, or by avoiding conditions that may cause the cough syncope. In addition, cough suppression modalities can also be used. We herein report 3 cases of cough syncope presenting in lung cancer patients.
이수현(Su-Hyun Lee),류시영(Si-Young You),최현주(Hyun-Joo Choi),조정해(Jung-Hae Cho),김성환(Sung-Whan Kim),이종환(Jong-Hwan Lee),김영운(Young-Woon Kim),김훈교(Hoon-Kyo Kim) 대한두경부종양학회 2012 대한두경부 종양학회지 Vol.28 No.1
Small cell carcinoma mainly occurs in the lung. Approximately 2.5-5% of small cell carcinomas are prima-ry extrapulmonary which are commonly found in the esophagus, GI tract, skin, uterus, and urinary tract.Small cell carcinoma of the head and neck is extremely rare and its prognosis is poor.We report a case of supraglottic small cell carcinoma with cervical lymph node and rib metastasis in a 75-year-old man. The patient was treat-ed with sequential combination of chemotherapy and radiotherapy, but the cancer has progressed.We conclud-ed that we have to find an effective therapy for laryngeal small cell carcinoma.
증례 : 순환기 ; 좌회선지 원위부에서 우관상동맥이 기원하는 단일 관상동맥 기형 1예
박하욱 ( Ha Wook Park ),류시영 ( Si Young You ),윤재승 ( Jae Seung Yun ),이해미 ( Hae Mi Lee ),이수연 ( Soo Yeon Lee ),정욱성 ( Wook Sung Chung ),오용석 ( Yong Seog Oh ) 대한내과학회 2011 대한내과학회지 Vol.80 No.2S
선천성 심장이상을 동반하지 않은 단일 관상동맥 기형은 매우 드물고, 특히 우관상동맥이 좌회선지의 원위부에서 기시하는 경우는 현재까지 국내에서 1예, 전 세계적으로는 18예에서만 보고되었다. 단일 관상동맥 기형은 분류에 따라 급성 심장사를 일으킬 수 있는 경우가 있어 임상적으로 중요한 의의를 갖지만, 환자의 평가 및 치료에는 정확한 지침이 없는 실정이다. 저자들은 미세혈관 협심증으로 진단된 좌회선지 원위부에서 기원하는 우관상동맥을 보이는 단일 관상동맥 기형 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Single coronary artery (SCA) is a rare congenital anomaly and commonly associated with other congenital cardiac malformations. Some subgroups of SCA can lead to angina pectoris, acute myocardial infarction, or even sudden cardiac death in the absence of atherosclerosis. An anomalous origin of the right coronary artery, arising from the distal portion of the left circumflex artery, has previously been reported in a few cases. In this article, we report a case of a right coronary artery arising from the distal portion of the left circumflex artery with no other cardiac congenital anomaly. (Korean J Med 2011;80:S172-S177)
박지찬,장이선,전은경,김동규,이욱현,이국진,류시영,최현호,박석영,Park, Ji-Chan,Jang, Yi-Sun,Jeon, Eun-Kyoung,Kim, Dong-Kyu,Lee, Wook-Hyun,Lee, Guk-Jin,You, Si-Young,Choi, Hyun-Ho,Park, Suk-Young 한국호스피스완화의료학회 2009 한국호스피스.완화의료학회지 Vol.12 No.4
목적: 진행성 암 환자에서 악성장폐색은 구역, 구토, 통증을 비롯한 소화기계 증상을 유발하여 삶의 질을 저하시킨다. 악성장폐색의 증상 조절을 위해 octreotide를 투여한 후의 효능에 대한 보고들이 발표되었고, 저자들은 악성장폐색이 있는 환자에게 보존적 치료에 octreotide를 추가하여 투여시의 효과와 안전성을 알아보고자 하였다. 방법: 의무기록을 통하여 일반적인 치료로 호전이 없어 octreotide를 추가한 악성장폐색의 환자 29명에서 octretide를 0.1 mg을 시작으로 증상 조절될 때까지 증량하여, 약 투여 전후의 통증의 변화, 구토 횟수의 변화, 비위관 삽입환자의 경우 배액량의 변화를 조사하였다. 결과: Octreotide 투여량의 중간 값은 0.2 mg이고 0.1~0.6 mg의 범위이며, 약제 투여시점으로부터 사망까지 2일에서 103일의 범위로 중간 값은 20일이었다. 약제 투여 전의 VAS는 평균 5.6$\pm$1.2이고, 약 투여 후 VAS의 평균은 2.7$\pm$1.0이었으며 통계적으로 유의한 감소를 보였다(P<0.05). 약제 투여 전의 구토 횟수는 평균 3.6회/일$\pm$2.5이었고 약 투여 후에는 0.4회/일$\pm$0.8로 감소되었고, 통계적으로 유의한 감소를 보였다(P<0.05). 약제 투여전에 비위관 삽입 환자는 평균 975$\pm$1,083 cc/일의 배액이 확인되었고, 약 투여 후에는 평균 115$\pm$196 cc/일로 유의하게 감소하였다(P<0.05). 결론: 일반적인 약물치료에 반응이 없는 악성장폐색환자에서 octretide의 추가 투여는 효과적이며 안전하였다. 악성장폐색 환자의 증상조절을 위해서 octreotide의 추가 투여를 적극적으로 고려해야 하겠다. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea Purpose: Malignant bowel obstruction causes gastrointestinal symptoms and leads to diminished quality of life in patients with advanced cancer. Several studies have shown the efficacy of octreotide for the relief of malignant bowel obstruction-related symptoms. The aim of this study is to assess the efficacy and safety of octreotide in patients with malignant bowel obstruction. Methods: We retrospectively reviewed medical records of twenty nine patients who had suffered from malignant bowel obstruction without clinical improvement of conservative care and subsequently, received octreotide treatment. Initial dosage of octreotide was 0.1 mg/day, and dose was escalated depending on the clinical effect. For each patient, we assessed visual analogue scale (VAS) of pain, number of vomiting episode, and amount of nasogastric tube drainage. Results: Median dosage of octreotide was 0.2 mg/day (range 0.1~0.6), and median duration from initial medication to death was 20 days (range 2~103). VAS before and after octreotide treatment were 5.6$\pm$1.24, and 2.7$\pm$0.96, respectively. The numbers of vomiting episode before and after octreotide treatment were 3.6/day$\pm$2.5, and 0.4/day$\pm$0.8, respectively. The mean amounts of nasogastric tube drainage before and after octreotide treatment were 975$\pm$1,083 cc/day and 115$\pm$196 cc/day, respectively. Statistically significant reduction in VAS, the number of vomiting episode and the amount of nasogastric tube drainage were observed after octreotide treatment (P<0.05). Conclusion: Administration of octreotide in patients with malignant bowel obstruction, which is uncontrolled by other medication, was effective and safe. In such clinical situations, physicians should consider to add of octreotide for symptomatic control.